Pliant Therapeutics Inc (PLRX) — Who's Buying and Selling (13F, Q2 2026)

PLRX ranks #4937 out of 37501 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

PLRX is a disclosed holding of Two Sigma (Two Sigma Investments), one of the tracked superinvestors on AlphaSMO — it makes up 0.0% of that fund's own 13F portfolio.

86 institutions disclose a position in PLRX, but none treat it as a major bet — even Peapod Lane Capital LLC, its most concentrated holder, allocates just 1.0% of its own portfolio to it.

ADAR1 Capital Management, LLC has added to its PLRX position for two straight quarters, increasing it by $6.2M to reach $6.3M today.

Redmile Group, LLC has trimmed its PLRX position for two straight quarters, cutting it by $1.1M while still holding $880.2K.

PLRX is up 4.5% today, and institutions have been net buyers of $2.6M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

PLRX reported a net loss of $92.3M over the trailing twelve months.

• Not yet profitable — net loss of $92.3M over the trailing twelve months
• Revenue declined 100.0% year over year
• Net income improved year over year, from -$207.0M to -$92.3M
• Operating cash flow was negative, using $128.3M in cash
• Current ratio of 12.00x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.24x equity — within a conventional range